Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16ClNO3.ClH |
Molecular Weight | 294.174 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1
InChI
InChIKey=FIVHOHCAXWQPGC-UHFFFAOYSA-N
InChI=1S/C12H16ClNO3.ClH/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11;/h3-6H,7-9H2,1-2H3;1H
Molecular Formula | C12H16ClNO3 |
Molecular Weight | 257.713 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://smart-drugs.net/article-lucidril.htmCurator's Comment: description was created based on several sources, including
http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/
Sources: http://smart-drugs.net/article-lucidril.htm
Curator's Comment: description was created based on several sources, including
http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/
Meclofenoxate (INN, BAN) (brand name Lucidril), also known as centrophenoxine, is a cholinergic nootropic used as a dietary supplement and drug in the treatment of symptoms of senile dementia and Alzheimer's disease. Meclofenoxate has been shown in studies to be effective in enhancing the memory and in improving the cognitive functions of the elderly. Some studies even suggest that Meclofenoxate has the ability to reverse the signs of brain aging. While claims about its ability as a nootropic agent have not been fully established in clinical trials, some studies do strongly suggest that it is indeed very effective in improving memory retention and recall. Meclofenoxate HCL Powder for Injection is also indicated for the following conditions: comma; skull and brain trauma; following a stroke; encephalopathy; mental disorders (in combination with psychotropic agents); mental and psychomotor retardation in children; brain intoxication; alcohol psychoses; neuritis and polyneuritis. The main mechanism of action of Meclofenoxate is generally believed to be cholinergic in nature. As an efficient transporter of DMAE, Meclofenoxate encourages the production of choline in the brain, which is then synthesized into acetylcholine. The more acetylcholine neurotransmitters in the brain, the better and more efficient the cognitive functions will be. Meclofenoxate also increases cellular membrane phospholipids
CNS Activity
Sources: http://nootropicsupplementreview.com/meclofenoxate/
Curator's Comment: Meclofenoxate increases the dimethylethanolamine or DMAE levels in the brain. DMAE is a precursor of acetylcholine, an important neurotransmitter in the brain believed to be responsible for most of the cognitive processes within it.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? | 2001 Feb |
|
Cholinergic medication for neuroleptic-induced tardive dyskinesia. | 2002 |
|
Pharmacological interventions against aging through the cell plasma membrane: a review of the experimental results obtained in animals and humans. | 2002 Apr |
|
Brain cholinesterases: III. Future perspectives of AD research and clinical practice. | 2004 |
|
Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. | 2004 Dec |
|
Therapy of hearing disorders - conservative procedures. | 2005 |
|
[Effects of piracetam and meclofenoxate on the brain NMDA and nicotinic receptors in mice with different exploratory efficacy in the cross maze test]. | 2008 Jan-Feb |
|
Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. | 2008 Mar 27 |
|
Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. | 2008 Sep |
|
Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. | 2009 Nov |
|
[Transcutaneous electrical acupoint stimulation combined with auricular acupoint sticking for treatment of primary nocturnal enuresis]. | 2010 May |
|
A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma. | 2010 May-Jun |
Patents
Sample Use Guides
Elderly people with significant intellectual decline may chose 3 to 6 Centrophenoxine tablets (250 mg) per day taken preferably with breakfast and lunch, in order to avoid insomnia.
For the non-elderly wishing to utilize the brain boosting benefits of Centrophenoxine, perhaps only 1 or 2 Centrophenoxine tablets (250 mg each) daily with breakfast or lunch.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3018064
The superoxide radical scavenging ability of centrophenoxine (CPH/MECLOFENOXATE) was studied in vitro using the method of pyrogallol autoxidation, cytochrome c reduction and photoxidation of o-dianisidine in salt-free assay media and in the presence of increasing NaCl or KCl concentrations. The CPH proved to be a superoxide radical scavenger in all three systems used, however, the rate constant for this reaction was rather low (1.7 X 10(2) M-1 s-1).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:53:07 GMT 2023
by
admin
on
Fri Dec 15 18:53:07 GMT 2023
|
Record UNII |
5BK3070BDY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
113619
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
100000086164
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
m7121
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL64545
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
DTXSID8045141
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
236572
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | RxNorm | ||
|
222-975-3
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
SUB03107MIG
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
3685-84-5
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
5BK3070BDY
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
4268
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY | |||
|
19379
Created by
admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |